NCT03266965View on ClinicalTrials.gov

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

August 7, 2020

Study Completion Date

August 7, 2020

Conditions
Multiple Sclerosis
Interventions
DRUG

Carbidopa

All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.

DIETARY_SUPPLEMENT

L-Histidine

Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Miami

OTHER

NCT03266965 - Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach | Biotech Hunter | Biotech Hunter